Breaking News

Yesterday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Recommendations
Moderna's Phase 3 data on COVID vaccine could come by October, says Jefferies » 06:55
08/03/20
08/03
06:55
08/03/20
06:55
MRNA

Moderna

$74.10 /

-3.5 (-4.51%)

, PFE

Pfizer

$38.48 /

-0.27 (-0.70%)

, BNTX

BioNTech

$82.12 /

-1.895 (-2.26%)

, AZN

AstraZeneca

$55.77 /

-2.13 (-3.68%)

Jefferies analyst Michael…

Jefferies analyst Michael Yee said he sees fast enrollment in the Phase 3 study of Moderna's (MRNA) COVID-19 vaccine, along with above-average infection rates in U.S. hot spots, leaving 70% odds that the trial could meet its primary endpoint before the end of October to early November based on the first or second interim. Yee believes Moderna's Phase 3 trial has a 65% chance of working and with data coming potentially as soon as October he thinks emergency use authorization approval is potentially possible by the end of 2020. He sees similar, if not earlier into September, timing for the vaccine candidate being studied by Pfizer (PFE) and BioNTech (BNTX), due to global enrollment and other minor details, Yee added. He also estimates Oxford and AstraZeneca's (AZN) data may read out by Fall given more EU based enrollment and infection rate sensitivities, the analyst noted.

ShowHide Related Items >><<
PFE Pfizer
$38.48 /

-0.27 (-0.70%)

MRNA Moderna
$74.10 /

-3.5 (-4.51%)

BNTX BioNTech
$82.12 /

-1.895 (-2.26%)

AZN AstraZeneca
$55.77 /

-2.13 (-3.68%)

MRNA Moderna
$74.10 /

-3.5 (-4.51%)

07/30/20 BofA
BofA says hard to compare Moderna COVID data to competing preclinical data
07/27/20 Piper Sandler
Piper reiterates $134 Moderna target on start of Phase III vaccine trial
07/27/20 BMO Capital
Moderna price target lowered to $94 from $112 at BMO Capital
07/24/20 Baird
Arbutus Biopharma upside priced in, Baird downgrades to Neutral
PFE Pfizer
$38.48 /

-0.27 (-0.70%)

07/30/20 Morgan Stanley
Pfizer price target raised to $42 from $36 at Morgan Stanley
07/30/20 Mizuho
Pfizer price target raised to $43 from $38 at Mizuho
07/28/20 SVB Leerink
Solid Biosciences downgraded to Market Perform at SVB Leerink
BNTX BioNTech
$82.12 /

-1.895 (-2.26%)

07/21/20
Fly Intel: Top five analyst upgrades
07/21/20 Canaccord
BioNTech price target raised to $97 from $75 at Canaccord
AZN AstraZeneca
$55.77 /

-2.13 (-3.68%)

07/31/20 Barclays
Barclays backs Overweight on AstraZeneca after Q2 results
07/29/20 Barclays
AstraZeneca price target raised to 9,300 GBp from 9,200 GBp at Barclays
07/20/20 Jefferies
AstraZeneca slide 'overdone' after 'encouraging' vaccine data, says Jefferies
PFE Pfizer
$38.48 /

-0.27 (-0.70%)

MRNA Moderna
$74.10 /

-3.5 (-4.51%)

BNTX BioNTech
$82.12 /

-1.895 (-2.26%)

AZN AstraZeneca
$55.77 /

-2.13 (-3.68%)

  • 23
    Jul
  • 19
    May
  • 12
    Feb
  • 06
    Feb
  • 10
    Oct
PFE Pfizer
$38.48 /

-0.27 (-0.70%)

MRNA Moderna
$74.10 /

-3.5 (-4.51%)

BNTX BioNTech
$82.12 /

-1.895 (-2.26%)

AZN AstraZeneca
$55.77 /

-2.13 (-3.68%)

PFE Pfizer
$38.48 /

-0.27 (-0.70%)

MRNA Moderna
$74.10 /

-3.5 (-4.51%)

BNTX BioNTech
$82.12 /

-1.895 (-2.26%)

AZN AstraZeneca
$55.77 /

-2.13 (-3.68%)

PFE Pfizer
$38.48 /

-0.27 (-0.70%)

MRNA Moderna
$74.10 /

-3.5 (-4.51%)

BNTX BioNTech
$82.12 /

-1.895 (-2.26%)

AZN AstraZeneca
$55.77 /

-2.13 (-3.68%)

Saturday
On The Fly
Week in review: How Trump's policies moved stocks » 09:06
08/01/20
08/01
09:06
08/01/20
09:06
MSFT

Microsoft

$205.00 /

+1.135 (+0.56%)

, PFE

Pfizer

$38.48 /

-0.27 (-0.70%)

, AZN

AstraZeneca

$55.77 /

-2.13 (-3.68%)

, BMY

Bristol-Myers

$58.66 /

-0.22 (-0.37%)

, LLY

Eli Lilly

$150.24 /

-2.71 (-1.77%)

, GSK

GlaxoSmithKline

$40.31 /

+0.045 (+0.11%)

, JNJ

Johnson & Johnson

$145.78 /

-1.09 (-0.74%)

, MRK

Merck

$80.26 /

+1.21 (+1.53%)

, NVS

Novartis

$82.09 /

-2.115 (-2.51%)

, SNY

Sanofi

$52.43 /

-0.1 (-0.19%)

, MRNA

Moderna

$74.10 /

-3.5 (-4.51%)

, SNAP

Snap

$22.41 /

+ (+0.00%)

, TWTR

Twitter

$36.39 /

-0.34 (-0.93%)

, FB

Facebook

$253.82 /

+19.19 (+8.18%)

, GOOG

Alphabet

$1,482.46 /

-52.125 (-3.40%)

, GOOGL

Alphabet Class A

$1,487.69 /

-48.81 (-3.18%)

, AMZN

Amazon.com

$3,165.00 /

+114.03 (+3.74%)

, AAPL

Apple

$425.02 /

+39.88 (+10.35%)

, KODK

Eastman Kodak

$22.30 /

-7.53 (-25.24%)

, RHHBY

Roche

$0.00 /

+ (+0.00%)

Catch up on the top…

Open Full Text

ShowHide Related Items >><<
TWTR Twitter
$36.39 /

-0.34 (-0.93%)

SNY Sanofi
$52.43 /

-0.1 (-0.19%)

SNAP Snap
$22.41 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PFE Pfizer
$38.48 /

-0.27 (-0.70%)

NVS Novartis
$82.09 /

-2.115 (-2.51%)

MSFT Microsoft
$205.00 /

+1.135 (+0.56%)

MRNA Moderna
$74.10 /

-3.5 (-4.51%)

MRK Merck
$80.26 /

+1.21 (+1.53%)

LLY Eli Lilly
$150.24 /

-2.71 (-1.77%)

KODK Eastman Kodak
$22.30 /

-7.53 (-25.24%)

JNJ Johnson & Johnson
$145.78 /

-1.09 (-0.74%)

GSK GlaxoSmithKline
$40.31 /

+0.045 (+0.11%)

GOOGL Alphabet Class A
$1,487.69 /

-48.81 (-3.18%)

GOOG Alphabet
$1,482.46 /

-52.125 (-3.40%)

FB Facebook
$253.82 /

+19.19 (+8.18%)

BMY Bristol-Myers
$58.66 /

-0.22 (-0.37%)

AZN AstraZeneca
$55.77 /

-2.13 (-3.68%)

AMZN Amazon.com
$3,165.00 /

+114.03 (+3.74%)

AAPL Apple
$425.02 /

+39.88 (+10.35%)

MSFT Microsoft
$205.00 /

+1.135 (+0.56%)

07/31/20 Stifel
Citrix disclosure points to $1B commitment, most likely to Azure, says Stifel
07/27/20 Morgan Stanley
Morgan Stanley downgrades Software industry view to In-Line from Attractive
07/23/20
Fly Intel: Top five analyst downgrades
07/23/20 Wedbush
Microsoft remains top cloud name at Wedbush
PFE Pfizer
$38.48 /

-0.27 (-0.70%)

07/30/20 BofA
BofA says hard to compare Moderna COVID data to competing preclinical data
07/30/20 Morgan Stanley
Pfizer price target raised to $42 from $36 at Morgan Stanley
07/30/20 Mizuho
Pfizer price target raised to $43 from $38 at Mizuho
07/28/20 SVB Leerink
Solid Biosciences downgraded to Market Perform at SVB Leerink
AZN AstraZeneca
$55.77 /

-2.13 (-3.68%)

07/31/20 Barclays
Barclays backs Overweight on AstraZeneca after Q2 results
07/29/20 Barclays
AstraZeneca price target raised to 9,300 GBp from 9,200 GBp at Barclays
07/20/20 Jefferies
AstraZeneca slide 'overdone' after 'encouraging' vaccine data, says Jefferies
BMY Bristol-Myers
$58.66 /

-0.22 (-0.37%)

07/28/20 Mizuho
Wait for Bristol-Myers' bb2121 submission making some 'nervous,' says Mizuho
07/28/20
Fly Intel: Top five analyst initiations
07/28/20 Raymond James
Bristol-Myers initiated with an Outperform at Raymond James
07/22/20 Morgan Stanley
Morgan Stanley sees 'encouraging news' coming in near-term for Bristol-Myers
LLY Eli Lilly
$150.24 /

-2.71 (-1.77%)

07/31/20 Barclays
Eli Lilly earnings selloff 'meaningful over-reaction,' says Barclays
07/15/20 H.C. Wainwright
Blueprint Medicines price target raised to $110 from $66 at H.C. Wainwright
07/14/20 Baird
Blueprint Medicines price target raised to $100 from $90 at Baird
07/14/20 Raymond James
Blueprint Medicines price target raised to $106 from $95 at Raymond James
GSK GlaxoSmithKline
$40.31 /

+0.045 (+0.11%)

07/31/20 Barclays
Barclays backs Underweight on GSK after 'challenging' Q2
07/30/20 Roth Capital
Roth Capital bullish on Ideaya as GSK highlights synthetic lethality pipeline
07/13/20 UBS
UBS reiterates Buy on GSK as FDA belantamab docs are out
07/13/20 JPMorgan
Ideaya upgraded to Overweight on recent pullback at JPMorgan
JNJ Johnson & Johnson
$145.78 /

-1.09 (-0.74%)

07/29/20 Laidlaw
Curis initiated with a Buy at Laidlaw
07/17/20 Goldman Sachs
J&J valuation discount to S&P 500 'too wide,' says Goldman Sachs
07/17/20 Citi
Johnson & Johnson price target raised to $170 from $165 at Citi
MRK Merck
$80.26 /

+1.21 (+1.53%)

07/27/20 H.C. Wainwright
Agreement termination 'optimal' for Vyleesi future, says H.C. Wainwright
06/30/20 SVB Leerink
Seattle Genetics price target raised to $167 from $155 at SVB Leerink
06/30/20 Oppenheimer
Seattle Genetics price target raised to $210 from $200 at Oppenheimer
NVS Novartis
$82.09 /

-2.115 (-2.51%)

07/28/20 Morgan Stanley
Novartis price target raised to CHF 93 from CHF 91 at Morgan Stanley
07/01/20 Piper Sandler
Amgen appeal rules in favor of patent validity, says Piper Sandler
07/01/20 Jefferies
Amgen win on Enbrel patent removes key overhang, says Jefferies
07/01/20 Goldman Sachs
Global Blood Therapeutics upgraded to Buy from Neutral at Goldman Sachs
SNY Sanofi
$52.43 /

-0.1 (-0.19%)

07/31/20 JPMorgan
Sanofi price target raised to EUR 106 from EUR 103 at JPMorgan
07/20/20 BMO Capital
Immunic initiated with an Outperform at BMO Capital
07/08/20 Piper Sandler
Piper upgrades Kiadis on 'platform validating' Sanofi deal
07/06/20 Citi
BioMarin price target raised to $148 from $105 at Citi
MRNA Moderna
$74.10 /

-3.5 (-4.51%)

07/27/20 Piper Sandler
Piper reiterates $134 Moderna target on start of Phase III vaccine trial
07/27/20 BMO Capital
Moderna price target lowered to $94 from $112 at BMO Capital
07/24/20 Baird
Arbutus Biopharma upside priced in, Baird downgrades to Neutral
SNAP Snap
$22.41 /

+ (+0.00%)

07/28/20 Morgan Stanley
Morgan Stanley lowers near-term, long-term forecasts for Roku
07/22/20
Fly Intel: Top five analyst downgrades
07/22/20 Oppenheimer
Snap price target raised to $28 from $18 at Oppenheimer
07/22/20 JPMorgan
Snap should be bought on any meaningful pullback, says JPMorgan
TWTR Twitter
$36.39 /

-0.34 (-0.93%)

07/24/20 Truist
Twitter price target raised to $40 from $32 at SunTrust
07/24/20 Argus
Twitter price target raised to $46 from $40 at Argus
07/24/20 Canaccord
Twitter price target raised to $40 from $32 at Canaccord
FB Facebook
$253.82 /

+19.19 (+8.18%)

07/31/20
Facebook price target raised to $300 from $290 at JPMorgan
07/31/20 Wedbush
Facebook price target raised to $300 from $250 at Wedbush
07/31/20 RBC Capital
Facebook price target raised to $320 from $271 at RBC Capital
07/31/20 Raymond James
Facebook price target raised to $280 from $240 at Raymond James
GOOG Alphabet
$1,482.46 /

-52.125 (-3.40%)

07/31/20
Fly Intel: Top five analyst downgrades
07/31/20 Guggenheim
Alphabet price target raised to $1,725 from $1,580 at Guggenheim
07/31/20 Raymond James
Alphabet price target raised to $1,700 from $1,425 at Raymond James
07/31/20 Oppenheimer
Alphabet price target raised to $1,685 from $1,445 at Oppenheimer
GOOGL Alphabet Class A
$1,487.69 /

-48.81 (-3.18%)

07/31/20 RBC Capital
Alphabet price target raised to $1,700 from $1,500 at RBC Capital
07/31/20 Morgan Stanley
Alphabet price target raised to $1,760 from $1,700 at Morgan Stanley
07/31/20 Barclays
Alphabet price target raised to $1,800 from $1,600 at Barclays
AMZN Amazon.com
$3,165.00 /

+114.03 (+3.74%)

07/31/20 BMO Capital
Amazon.com price target raised to $3,700 from $3,500 at BMO Capital
07/31/20 RBC Capital
Amazon.com price target raised to $3,800 from $3,300 at RBC Capital
07/31/20 Guggenheim
Amazon.com price target raised to $3,600 from $2,700 at Guggenheim
07/31/20 Goldman Sachs
Amazon.com price target raised to $4,200 from $3,800 at Goldman Sachs
AAPL Apple
$425.02 /

+39.88 (+10.35%)

07/31/20 Canaccord
Canaccord boosts Apple target to $460 after 'impressive' quarter
07/31/20 RBC Capital
Apple price target raised to $445 from $390 at RBC Capital
07/31/20
Apple price target raised to $460 from $425 at JPMorgan
07/31/20 Loop Capital
Apple price target raised to $376 from $330 at Loop Capital
KODK Eastman Kodak
$22.30 /

-7.53 (-25.24%)

RHHBY Roche
$0.00 /

+ (+0.00%)

07/29/20 UBS
Roche price target raised to CHF 390 from CHF 380 at UBS
07/29/20 Morgan Stanley
Roche price target raised to CHF 375 from CHF 370 at Morgan Stanley
07/24/20 Credit Suisse
Credit Suisse backs Neutral on Roche after H1 results
07/24/20 UBS
Roche Q2 sales weak but recovery in June is evident, says UBS
TWTR Twitter
$36.39 /

-0.34 (-0.93%)

SNY Sanofi
$52.43 /

-0.1 (-0.19%)

SNAP Snap
$22.41 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PFE Pfizer
$38.48 /

-0.27 (-0.70%)

NVS Novartis
$82.09 /

-2.115 (-2.51%)

MSFT Microsoft
$205.00 /

+1.135 (+0.56%)

MRNA Moderna
$74.10 /

-3.5 (-4.51%)

MRK Merck
$80.26 /

+1.21 (+1.53%)

LLY Eli Lilly
$150.24 /

-2.71 (-1.77%)

JNJ Johnson & Johnson
$145.78 /

-1.09 (-0.74%)

GSK GlaxoSmithKline
$40.31 /

+0.045 (+0.11%)

GOOG Alphabet
$1,482.46 /

-52.125 (-3.40%)

FB Facebook
$253.82 /

+19.19 (+8.18%)

BMY Bristol-Myers
$58.66 /

-0.22 (-0.37%)

AZN AstraZeneca
$55.77 /

-2.13 (-3.68%)

AMZN Amazon.com
$3,165.00 /

+114.03 (+3.74%)

AAPL Apple
$425.02 /

+39.88 (+10.35%)

  • 19
    May
  • 12
    Feb
TWTR Twitter
$36.39 /

-0.34 (-0.93%)

SNY Sanofi
$52.43 /

-0.1 (-0.19%)

SNAP Snap
$22.41 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PFE Pfizer
$38.48 /

-0.27 (-0.70%)

NVS Novartis
$82.09 /

-2.115 (-2.51%)

MSFT Microsoft
$205.00 /

+1.135 (+0.56%)

MRNA Moderna
$74.10 /

-3.5 (-4.51%)

MRK Merck
$80.26 /

+1.21 (+1.53%)

LLY Eli Lilly
$150.24 /

-2.71 (-1.77%)

KODK Eastman Kodak
$22.30 /

-7.53 (-25.24%)

JNJ Johnson & Johnson
$145.78 /

-1.09 (-0.74%)

GSK GlaxoSmithKline
$40.31 /

+0.045 (+0.11%)

GOOG Alphabet
$1,482.46 /

-52.125 (-3.40%)

BMY Bristol-Myers
$58.66 /

-0.22 (-0.37%)

AZN AstraZeneca
$55.77 /

-2.13 (-3.68%)

AMZN Amazon.com
$3,165.00 /

+114.03 (+3.74%)

AAPL Apple
$425.02 /

+39.88 (+10.35%)

TWTR Twitter
$36.39 /

-0.34 (-0.93%)

SNY Sanofi
$52.43 /

-0.1 (-0.19%)

SNAP Snap
$22.41 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PFE Pfizer
$38.48 /

-0.27 (-0.70%)

NVS Novartis
$82.09 /

-2.115 (-2.51%)

MSFT Microsoft
$205.00 /

+1.135 (+0.56%)

MRNA Moderna
$74.10 /

-3.5 (-4.51%)

MRK Merck
$80.26 /

+1.21 (+1.53%)

LLY Eli Lilly
$150.24 /

-2.71 (-1.77%)

GSK GlaxoSmithKline
$40.31 /

+0.045 (+0.11%)

GOOGL Alphabet Class A
$1,487.69 /

-48.81 (-3.18%)

FB Facebook
$253.82 /

+19.19 (+8.18%)

BMY Bristol-Myers
$58.66 /

-0.22 (-0.37%)

AZN AstraZeneca
$55.77 /

-2.13 (-3.68%)

TWTR Twitter
$36.39 /

-0.34 (-0.93%)

SNY Sanofi
$52.43 /

-0.1 (-0.19%)

SNAP Snap
$22.41 /

+ (+0.00%)

PFE Pfizer
$38.48 /

-0.27 (-0.70%)

NVS Novartis
$82.09 /

-2.115 (-2.51%)

MSFT Microsoft
$205.00 /

+1.135 (+0.56%)

MRNA Moderna
$74.10 /

-3.5 (-4.51%)

MRK Merck
$80.26 /

+1.21 (+1.53%)

LLY Eli Lilly
$150.24 /

-2.71 (-1.77%)

KODK Eastman Kodak
$22.30 /

-7.53 (-25.24%)

JNJ Johnson & Johnson
$145.78 /

-1.09 (-0.74%)

GSK GlaxoSmithKline
$40.31 /

+0.045 (+0.11%)

GOOGL Alphabet Class A
$1,487.69 /

-48.81 (-3.18%)

GOOG Alphabet
$1,482.46 /

-52.125 (-3.40%)

FB Facebook
$253.82 /

+19.19 (+8.18%)

BMY Bristol-Myers
$58.66 /

-0.22 (-0.37%)

AZN AstraZeneca
$55.77 /

-2.13 (-3.68%)

AMZN Amazon.com
$3,165.00 /

+114.03 (+3.74%)

AAPL Apple
$425.02 /

+39.88 (+10.35%)

MSFT Microsoft
$205.00 /

+1.135 (+0.56%)

GOOG Alphabet
$1,482.46 /

-52.125 (-3.40%)

AMZN Amazon.com
$3,165.00 /

+114.03 (+3.74%)

Friday
Recommendations
Barclays backs Overweight on AstraZeneca after Q2 results » 14:44
07/31/20
07/31
14:44
07/31/20
14:44
AZN

AstraZeneca

$55.55 /

-2.35 (-4.06%)

Barclays analyst Emmanuel…

Barclays analyst Emmanuel Papadakis reiterated an Overweight rating and GBp 9,300 price target on AstraZeneca after the company reported "solid and fairly plan" Q2 results. The analyst said the report reaffirmed his view that the story remains one of the most appealing in EU pharma given sustained momentum from the core oncology portfolio supplemented by a fairly consistent string of more positive pipeline newsflow and recent business development.

ShowHide Related Items >><<
AZN AstraZeneca
$55.55 /

-2.35 (-4.06%)

AZN AstraZeneca
$55.55 /

-2.35 (-4.06%)

07/30/20 BofA
BofA says hard to compare Moderna COVID data to competing preclinical data
07/29/20 Barclays
AstraZeneca price target raised to 9,300 GBp from 9,200 GBp at Barclays
07/20/20 Jefferies
AstraZeneca slide 'overdone' after 'encouraging' vaccine data, says Jefferies
06/24/20 Oddo BHF
AstraZeneca downgraded to Reduce from Buy at Oddo BHF
AZN AstraZeneca
$55.55 /

-2.35 (-4.06%)

AZN AstraZeneca
$55.55 /

-2.35 (-4.06%)

AZN AstraZeneca
$55.55 /

-2.35 (-4.06%)

AZN AstraZeneca
$55.55 /

-2.35 (-4.06%)

Thursday
Periodicals
AstraZeneca to be protected from COVID-19 vaccine liability claims, Reuters says » 15:39
07/30/20
07/30
15:39
07/30/20
15:39
AZN

AstraZeneca

$57.80 /

+1.225 (+2.17%)

AstraZeneca has been…

AstraZeneca has been awarded protection from future product liability claims related to its coronavirus vaccine candidate by most of the countries with which it has reached supply pacts, Reuters' Ludwig Burger and Pushkala Aripaka report, citing a senior executive. "This is a unique situation where we as a company simply cannot take the risk if in ... four years the vaccine is showing side effects," Ruud Dobber, a member of Astra's senior executive team, told Reuters. "In the contracts we have in place, we are asking for indemnification. For most countries it is acceptable to take that risk on their shoulders because it is in their national interest," he said, adding that the company and regulators were making safety and tolerability a top priority. Reference Link

ShowHide Related Items >><<
AZN AstraZeneca
$57.80 /

+1.225 (+2.17%)

AZN AstraZeneca
$57.80 /

+1.225 (+2.17%)

07/30/20 BofA
BofA says hard to compare Moderna COVID data to competing preclinical data
07/29/20 Barclays
AstraZeneca price target raised to 9,300 GBp from 9,200 GBp at Barclays
07/20/20 Jefferies
AstraZeneca slide 'overdone' after 'encouraging' vaccine data, says Jefferies
06/24/20 Oddo BHF
AstraZeneca downgraded to Reduce from Buy at Oddo BHF
AZN AstraZeneca
$57.80 /

+1.225 (+2.17%)

AZN AstraZeneca
$57.80 /

+1.225 (+2.17%)

AZN AstraZeneca
$57.80 /

+1.225 (+2.17%)

AZN AstraZeneca
$57.80 /

+1.225 (+2.17%)

Recommendations
BofA says hard to compare Moderna COVID data to competing preclinical data » 11:15
07/30/20
07/30
11:15
07/30/20
11:15
MRNA

Moderna

$77.48 /

-2 (-2.52%)

, PFE

Pfizer

$38.32 /

-0.19 (-0.49%)

, BNTX

BioNTech

$83.99 /

+1.575 (+1.91%)

, AZN

AstraZeneca

$57.30 /

+0.73 (+1.29%)

, MRK

Merck

$78.31 /

-1.02 (-1.29%)

, JNJ

Johnson & Johnson

$146.58 /

+0.04 (+0.03%)

Following the recent…

Following the recent publication of preclinical non-human primate data for Moderna's (MRNA) COVID-19 vaccine, mRNA-1273, BofA analyst Geoff Meacham said the data appear supportive of the "more important human data already published" from the phase 1 trial. While some may suggest transmissibility after vaccination with Moderna's vaccine will be lower than with the COVID-19 vaccine from Oxford and AstraZeneca (AZN), now known as AZD1222, "confounders in the data clouds any conclusion," he said. Meachem keeps a Neutral rating and $85 price target on Moderna, citing competing vaccines from Pfizer (PFE), AstraZeneca, J&J (JNJ), Merck (MRK) and others as well as his view of the "questionable economics to Moderna if a vaccine is approved."

ShowHide Related Items >><<
PFE Pfizer
$38.32 /

-0.19 (-0.49%)

MRNA Moderna
$77.48 /

-2 (-2.52%)

MRK Merck
$78.31 /

-1.02 (-1.29%)

JNJ Johnson & Johnson
$146.58 /

+0.04 (+0.03%)

BNTX BioNTech
$83.99 /

+1.575 (+1.91%)

AZN AstraZeneca
$57.30 /

+0.73 (+1.29%)

MRNA Moderna
$77.48 /

-2 (-2.52%)

07/27/20 Piper Sandler
Piper reiterates $134 Moderna target on start of Phase III vaccine trial
07/27/20 BMO Capital
Moderna price target lowered to $94 from $112 at BMO Capital
07/24/20 Baird
Arbutus Biopharma upside priced in, Baird downgrades to Neutral
07/23/20 SVB Leerink
Moderna initiated with a Market Perform at SVB Leerink
PFE Pfizer
$38.32 /

-0.19 (-0.49%)

07/30/20 Morgan Stanley
Pfizer price target raised to $42 from $36 at Morgan Stanley
07/30/20 Mizuho
Pfizer price target raised to $43 from $38 at Mizuho
07/28/20 SVB Leerink
Solid Biosciences downgraded to Market Perform at SVB Leerink
07/27/20 H.C. Wainwright
Agreement termination 'optimal' for Vyleesi future, says H.C. Wainwright
BNTX BioNTech
$83.99 /

+1.575 (+1.91%)

07/21/20
Fly Intel: Top five analyst upgrades
07/21/20 Canaccord
BioNTech price target raised to $97 from $75 at Canaccord
07/20/20 BofA
BioNTech upgraded to Buy from Neutral at BofA
AZN AstraZeneca
$57.30 /

+0.73 (+1.29%)

07/29/20 Barclays
AstraZeneca price target raised to 9,300 GBp from 9,200 GBp at Barclays
07/20/20 Jefferies
AstraZeneca slide 'overdone' after 'encouraging' vaccine data, says Jefferies
06/24/20 Oddo BHF
AstraZeneca downgraded to Reduce from Buy at Oddo BHF
06/23/20 Maxim
Inovio price target raised to $24 from $18 at Maxim
MRK Merck
$78.31 /

-1.02 (-1.29%)

06/30/20 SVB Leerink
Seattle Genetics price target raised to $167 from $155 at SVB Leerink
06/30/20 Oppenheimer
Seattle Genetics price target raised to $210 from $200 at Oppenheimer
06/25/20 Lake Street
Lake Street says Keytruda approval improves outlook for Checkpoint's cosibelimab
JNJ Johnson & Johnson
$146.58 /

+0.04 (+0.03%)

07/29/20 Laidlaw
Curis initiated with a Buy at Laidlaw
07/17/20 Goldman Sachs
J&J valuation discount to S&P 500 'too wide,' says Goldman Sachs
07/17/20 Citi
Johnson & Johnson price target raised to $170 from $165 at Citi
07/16/20 Goldman Sachs
J&J delay to robotic surgery program a positive for Intuitive, says Goldman
PFE Pfizer
$38.32 /

-0.19 (-0.49%)

MRNA Moderna
$77.48 /

-2 (-2.52%)

MRK Merck
$78.31 /

-1.02 (-1.29%)

JNJ Johnson & Johnson
$146.58 /

+0.04 (+0.03%)

BNTX BioNTech
$83.99 /

+1.575 (+1.91%)

AZN AstraZeneca
$57.30 /

+0.73 (+1.29%)

  • 23
    Jul
  • 19
    May
  • 12
    Feb
  • 06
    Feb
  • 10
    Oct
PFE Pfizer
$38.32 /

-0.19 (-0.49%)

MRNA Moderna
$77.48 /

-2 (-2.52%)

MRK Merck
$78.31 /

-1.02 (-1.29%)

JNJ Johnson & Johnson
$146.58 /

+0.04 (+0.03%)

BNTX BioNTech
$83.99 /

+1.575 (+1.91%)

PFE Pfizer
$38.32 /

-0.19 (-0.49%)

MRNA Moderna
$77.48 /

-2 (-2.52%)

MRK Merck
$78.31 /

-1.02 (-1.29%)

JNJ Johnson & Johnson
$146.58 /

+0.04 (+0.03%)

BNTX BioNTech
$83.99 /

+1.575 (+1.91%)

AZN AstraZeneca
$57.30 /

+0.73 (+1.29%)

PFE Pfizer
$38.32 /

-0.19 (-0.49%)

MRNA Moderna
$77.48 /

-2 (-2.52%)

MRK Merck
$78.31 /

-1.02 (-1.29%)

JNJ Johnson & Johnson
$146.58 /

+0.04 (+0.03%)

BNTX BioNTech
$83.99 /

+1.575 (+1.91%)

AZN AstraZeneca
$57.30 /

+0.73 (+1.29%)

Hot Stocks
Drug prices will soon be 'lowered massively' in U.S., Trump tweets » 09:51
07/30/20
07/30
09:51
07/30/20
09:51
JNJ

Johnson & Johnson

$147.11 /

+0.57 (+0.39%)

, LLY

Eli Lilly

$156.79 /

-5.03 (-3.11%)

, MRK

Merck

$78.20 /

-1.13 (-1.42%)

, PFE

Pfizer

$38.45 /

-0.06 (-0.16%)

, SNY

Sanofi

$51.85 /

-0.98 (-1.86%)

, AZN

AstraZeneca

$56.96 /

+0.39 (+0.69%)

, GSK

GlaxoSmithKline

$39.78 /

-0.82 (-2.02%)

, NVS

Novartis

$83.27 /

-1.08 (-1.28%)

, RHHBY

Roche

$0.00 /

+ (+0.00%)

, BMY

Bristol-Myers

$58.58 /

-0.58 (-0.98%)

President Donald Trump…

President Donald Trump tweeted: "Drug prices will soon be lowered massively. Big Pharma (Drug Companies) are advertising against me like crazy because lower prices mean less profit. When you watch a Fake Ad, just think lower drug prices!!!" Publicly traded companies in the space include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).

ShowHide Related Items >><<
SNY Sanofi
$51.85 /

-0.98 (-1.86%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PFE Pfizer
$38.45 /

-0.06 (-0.16%)

NVS Novartis
$83.27 /

-1.08 (-1.28%)

MRK Merck
$78.20 /

-1.13 (-1.42%)

LLY Eli Lilly
$156.79 /

-5.03 (-3.11%)

JNJ Johnson & Johnson
$147.11 /

+0.57 (+0.39%)

GSK GlaxoSmithKline
$39.78 /

-0.82 (-2.02%)

BMY Bristol-Myers
$58.58 /

-0.58 (-0.98%)

AZN AstraZeneca
$56.96 /

+0.39 (+0.69%)

JNJ Johnson & Johnson
$147.11 /

+0.57 (+0.39%)

07/29/20 Laidlaw
Curis initiated with a Buy at Laidlaw
07/17/20 Goldman Sachs
J&J valuation discount to S&P 500 'too wide,' says Goldman Sachs
07/17/20 Citi
Johnson & Johnson price target raised to $170 from $165 at Citi
07/16/20 Goldman Sachs
J&J delay to robotic surgery program a positive for Intuitive, says Goldman
LLY Eli Lilly
$156.79 /

-5.03 (-3.11%)

07/15/20 H.C. Wainwright
Blueprint Medicines price target raised to $110 from $66 at H.C. Wainwright
07/14/20 Baird
Blueprint Medicines price target raised to $100 from $90 at Baird
07/14/20 Raymond James
Blueprint Medicines price target raised to $106 from $95 at Raymond James
07/09/20 Morgan Stanley
Eli Lilly won't publish Phase 1 COVID antibody data, says Morgan Stanley
MRK Merck
$78.20 /

-1.13 (-1.42%)

07/27/20 H.C. Wainwright
Agreement termination 'optimal' for Vyleesi future, says H.C. Wainwright
06/30/20 SVB Leerink
Seattle Genetics price target raised to $167 from $155 at SVB Leerink
06/30/20 Oppenheimer
Seattle Genetics price target raised to $210 from $200 at Oppenheimer
06/25/20 Lake Street
Lake Street says Keytruda approval improves outlook for Checkpoint's cosibelimab
PFE Pfizer
$38.45 /

-0.06 (-0.16%)

07/30/20 Morgan Stanley
Pfizer price target raised to $42 from $36 at Morgan Stanley
07/30/20 Mizuho
Pfizer price target raised to $43 from $38 at Mizuho
07/28/20 SVB Leerink
Solid Biosciences downgraded to Market Perform at SVB Leerink
SNY Sanofi
$51.85 /

-0.98 (-1.86%)

07/20/20 BMO Capital
Immunic initiated with an Outperform at BMO Capital
07/08/20 Piper Sandler
Piper upgrades Kiadis on 'platform validating' Sanofi deal
07/06/20 Citi
BioMarin price target raised to $148 from $105 at Citi
07/01/20 Roth Capital
Applied Genetic may attract Sanofi takeover interest, says Roth Capital
AZN AstraZeneca
$56.96 /

+0.39 (+0.69%)

07/29/20 Barclays
AstraZeneca price target raised to 9,300 GBp from 9,200 GBp at Barclays
07/20/20 Jefferies
AstraZeneca slide 'overdone' after 'encouraging' vaccine data, says Jefferies
06/24/20 Oddo BHF
AstraZeneca downgraded to Reduce from Buy at Oddo BHF
06/23/20 Maxim
Inovio price target raised to $24 from $18 at Maxim
GSK GlaxoSmithKline
$39.78 /

-0.82 (-2.02%)

07/13/20 UBS
UBS reiterates Buy on GSK as FDA belantamab docs are out
07/13/20 JPMorgan
Ideaya upgraded to Overweight on recent pullback at JPMorgan
06/19/20 Barclays
Glaxo belantamab AdCom a surprise, supports cautious view, says Barclays
NVS Novartis
$83.27 /

-1.08 (-1.28%)

07/28/20 Morgan Stanley
Novartis price target raised to CHF 93 from CHF 91 at Morgan Stanley
07/01/20 Piper Sandler
Amgen appeal rules in favor of patent validity, says Piper Sandler
07/01/20 Jefferies
Amgen win on Enbrel patent removes key overhang, says Jefferies
07/01/20 Goldman Sachs
Global Blood Therapeutics upgraded to Buy from Neutral at Goldman Sachs
RHHBY Roche
$0.00 /

+ (+0.00%)

07/29/20 UBS
Roche price target raised to CHF 390 from CHF 380 at UBS
07/29/20 Morgan Stanley
Roche price target raised to CHF 375 from CHF 370 at Morgan Stanley
07/24/20 Credit Suisse
Credit Suisse backs Neutral on Roche after H1 results
07/24/20 UBS
Roche Q2 sales weak but recovery in June is evident, says UBS
BMY Bristol-Myers
$58.58 /

-0.58 (-0.98%)

07/28/20 Mizuho
Wait for Bristol-Myers' bb2121 submission making some 'nervous,' says Mizuho
07/28/20
Fly Intel: Top five analyst initiations
07/28/20 Raymond James
Bristol-Myers initiated with an Outperform at Raymond James
07/22/20 Morgan Stanley
Morgan Stanley sees 'encouraging news' coming in near-term for Bristol-Myers
SNY Sanofi
$51.85 /

-0.98 (-1.86%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PFE Pfizer
$38.45 /

-0.06 (-0.16%)

NVS Novartis
$83.27 /

-1.08 (-1.28%)

MRK Merck
$78.20 /

-1.13 (-1.42%)

LLY Eli Lilly
$156.79 /

-5.03 (-3.11%)

JNJ Johnson & Johnson
$147.11 /

+0.57 (+0.39%)

GSK GlaxoSmithKline
$39.78 /

-0.82 (-2.02%)

BMY Bristol-Myers
$58.58 /

-0.58 (-0.98%)

AZN AstraZeneca
$56.96 /

+0.39 (+0.69%)

SNY Sanofi
$51.85 /

-0.98 (-1.86%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PFE Pfizer
$38.45 /

-0.06 (-0.16%)

NVS Novartis
$83.27 /

-1.08 (-1.28%)

MRK Merck
$78.20 /

-1.13 (-1.42%)

LLY Eli Lilly
$156.79 /

-5.03 (-3.11%)

JNJ Johnson & Johnson
$147.11 /

+0.57 (+0.39%)

GSK GlaxoSmithKline
$39.78 /

-0.82 (-2.02%)

BMY Bristol-Myers
$58.58 /

-0.58 (-0.98%)

SNY Sanofi
$51.85 /

-0.98 (-1.86%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PFE Pfizer
$38.45 /

-0.06 (-0.16%)

NVS Novartis
$83.27 /

-1.08 (-1.28%)

MRK Merck
$78.20 /

-1.13 (-1.42%)

LLY Eli Lilly
$156.79 /

-5.03 (-3.11%)

JNJ Johnson & Johnson
$147.11 /

+0.57 (+0.39%)

GSK GlaxoSmithKline
$39.78 /

-0.82 (-2.02%)

BMY Bristol-Myers
$58.58 /

-0.58 (-0.98%)

AZN AstraZeneca
$56.96 /

+0.39 (+0.69%)

SNY Sanofi
$51.85 /

-0.98 (-1.86%)

PFE Pfizer
$38.45 /

-0.06 (-0.16%)

NVS Novartis
$83.27 /

-1.08 (-1.28%)

MRK Merck
$78.20 /

-1.13 (-1.42%)

LLY Eli Lilly
$156.79 /

-5.03 (-3.11%)

JNJ Johnson & Johnson
$147.11 /

+0.57 (+0.39%)

GSK GlaxoSmithKline
$39.78 /

-0.82 (-2.02%)

BMY Bristol-Myers
$58.58 /

-0.58 (-0.98%)

AZN AstraZeneca
$56.96 /

+0.39 (+0.69%)

Hot Stocks
AstraZeneca says nirsevimab reduced LRTI in Phase 2b trial » 06:51
07/30/20
07/30
06:51
07/30/20
06:51
AZN

AstraZeneca

$56.57 /

+0.27 (+0.48%)

Nirsevimab showed a…

Nirsevimab showed a significant reduction in medically-attended lower respiratory tract infections, or LRTI, and hospitalizations caused by respiratory syncytial virus, or RSV, in healthy preterm infants in a positive Phase IIb trial published in the New England Journal of Medicine, AstraZeneca announced. "The trial demonstrated for the first time that a single-dose monoclonal antibody can significantly reduce medically-attended RSV LRTI, including bronchiolitis and pneumonia, in infants throughout the full RSV season," the company said.

ShowHide Related Items >><<
AZN AstraZeneca
$56.57 /

+0.27 (+0.48%)

AZN AstraZeneca
$56.57 /

+0.27 (+0.48%)

07/29/20 Barclays
AstraZeneca price target raised to 9,300 GBp from 9,200 GBp at Barclays
07/20/20 Jefferies
AstraZeneca slide 'overdone' after 'encouraging' vaccine data, says Jefferies
06/24/20 Oddo BHF
AstraZeneca downgraded to Reduce from Buy at Oddo BHF
06/23/20 Maxim
Inovio price target raised to $24 from $18 at Maxim
AZN AstraZeneca
$56.57 /

+0.27 (+0.48%)

AZN AstraZeneca
$56.57 /

+0.27 (+0.48%)

AZN AstraZeneca
$56.57 /

+0.27 (+0.48%)

AZN AstraZeneca
$56.57 /

+0.27 (+0.48%)

Hot Stocks
AstraZeneca reports Tagrisso granted Breakthrough Therapy Designation in U.S. » 06:49
07/30/20
07/30
06:49
07/30/20
06:49
AZN

AstraZeneca

$56.57 /

+0.27 (+0.48%)

AstraZeneca announced…

AstraZeneca announced Tagrisso has been granted Breakthrough Therapy Designation in the U.S. for the adjuvant treatment of patients with early-stage epidermal growth factor receptor-mutated non-small cell lung cancer, or NSCLC, after complete tumor resection with curative intent. Jose Baselga, Executive Vice President, Oncology R&D said: "Patients with early-stage EGFRm lung cancer often experience recurrence even after successful surgery and adjuvant chemotherapy, yet there are currently no approved targeted treatments to improve outcomes. The Phase III ADAURA trial with Tagrisso demonstrated an unprecedented level of clinical benefit in these patients, and we are working closely with the FDA to deliver this potentially curative treatment to patients as quickly as possible."

ShowHide Related Items >><<
AZN AstraZeneca
$56.57 /

+0.27 (+0.48%)

AZN AstraZeneca
$56.57 /

+0.27 (+0.48%)

07/29/20 Barclays
AstraZeneca price target raised to 9,300 GBp from 9,200 GBp at Barclays
07/20/20 Jefferies
AstraZeneca slide 'overdone' after 'encouraging' vaccine data, says Jefferies
06/24/20 Oddo BHF
AstraZeneca downgraded to Reduce from Buy at Oddo BHF
06/23/20 Maxim
Inovio price target raised to $24 from $18 at Maxim
AZN AstraZeneca
$56.57 /

+0.27 (+0.48%)

AZN AstraZeneca
$56.57 /

+0.27 (+0.48%)

AZN AstraZeneca
$56.57 /

+0.27 (+0.48%)

AZN AstraZeneca
$56.57 /

+0.27 (+0.48%)

Earnings
AstraZeneca backs FY20 mid- to high-teens percentage increase in core EPS » 06:48
07/30/20
07/30
06:48
07/30/20
06:48
AZN

AstraZeneca

$56.57 /

+0.27 (+0.48%)

AstraZeneca said…

AstraZeneca said financial guidance for FY 2020 is unchanged. Total revenue is expected to increase by a high single-digit to a low double-digit percentage and core EPS is expected to increase by a mid- to high-teens percentage. "AstraZeneca recognises the heightened risks and uncertainties from the impact of COVID-19 referred to later in this announcement. Variations in performance between quarters can be expected to continue," the company said.

ShowHide Related Items >><<
AZN AstraZeneca
$56.57 /

+0.27 (+0.48%)

AZN AstraZeneca
$56.57 /

+0.27 (+0.48%)

07/29/20 Barclays
AstraZeneca price target raised to 9,300 GBp from 9,200 GBp at Barclays
07/20/20 Jefferies
AstraZeneca slide 'overdone' after 'encouraging' vaccine data, says Jefferies
06/24/20 Oddo BHF
AstraZeneca downgraded to Reduce from Buy at Oddo BHF
06/23/20 Maxim
Inovio price target raised to $24 from $18 at Maxim
AZN AstraZeneca
$56.57 /

+0.27 (+0.48%)

AZN AstraZeneca
$56.57 /

+0.27 (+0.48%)

AZN AstraZeneca
$56.57 /

+0.27 (+0.48%)

AZN AstraZeneca
$56.57 /

+0.27 (+0.48%)

Earnings
AstraZeneca reports Q2 core EPS 96c, up 31% at CER » 06:45
07/30/20
07/30
06:45
07/30/20
06:45
AZN

AstraZeneca

$56.57 /

+0.27 (+0.48%)

Reports Q2 revenue…

Reports Q2 revenue $6.28B, up 11% at CER. CEO Pascal Soriot commented: "I want to thank my colleagues around the world for producing a strong performance in the first half of the year, delivering further revenue growth and another step forward in profitability and cash generation. I was particularly pleased with the robust growth in Emerging Markets and the success of our new medicines. We made further progress with our pipeline, highlighted by the overwhelming success of Tagrisso in the ADAURA trial and with Farxiga, which expanded its potential beyond diabetes. We are also pleased with our new collaboration with Daiichi Sankyo on DS-1062, which strengthens our growing Oncology portfolio. Furthermore, our company has mounted a significant response to COVID-19, with capacity to deliver over two billion doses of AZD1222, the accelerated development of our monoclonal antibodies and new trials for the use of Calquence and Farxiga to treat patients affected by the virus. Looking ahead, while we continue to anticipate variations in quarterly performance, the continuation of our strategy makes us confident about the future. We are retaining our full-year guidance that is underpinned by the focus on commercial execution and an exciting pipeline of new medicines."

ShowHide Related Items >><<
AZN AstraZeneca
$56.57 /

+0.27 (+0.48%)

AZN AstraZeneca
$56.57 /

+0.27 (+0.48%)

07/29/20 Barclays
AstraZeneca price target raised to 9,300 GBp from 9,200 GBp at Barclays
07/20/20 Jefferies
AstraZeneca slide 'overdone' after 'encouraging' vaccine data, says Jefferies
06/24/20 Oddo BHF
AstraZeneca downgraded to Reduce from Buy at Oddo BHF
06/23/20 Maxim
Inovio price target raised to $24 from $18 at Maxim
AZN AstraZeneca
$56.57 /

+0.27 (+0.48%)

AZN AstraZeneca
$56.57 /

+0.27 (+0.48%)

AZN AstraZeneca
$56.57 /

+0.27 (+0.48%)

AZN AstraZeneca
$56.57 /

+0.27 (+0.48%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.